Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-03-03Clinical Trial Update: Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults. [Phase 3]
A Phase 3 trial evaluated the efficacy and safety of vortioxetine for generalized anxiety disorder in adults; results were posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-02-11Clinical Trial Update: Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder [Phase 3]
A Phase 3 trial of quetiapine extended-release for major depressive disorder with comorbid generalized anxiety disorder was terminated, and …
-
FDA approval · 2014-02-07FDA Approved: BUSPIRONE HYDROCHLORIDE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved the original application for Buspirone hydrochloride (generic). The approval marks entry of a generic version manufactured by Z…
-
FDA approval · 2014-01-10FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for venlafaxine hydrochloride from Zydus Pharmaceuticals USA Inc., authorizing its manufacturing and…
-
FDA approval · 2014-01-08FDA Approved: DULOXETINE — Original Application (Zydus Lifesciences Limited)
FDA approved the original application for a duloxetine generic from Zydus Lifesciences Limited, enabling marketing for the same indications …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-12-31FDA Approved: PAROXETINE — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for a generic paroxetine hydrochloride product manufactured by NorthStar Rx LLC.
-
FDA approval · 2013-12-31FDA Approved: PAROXETINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Paroxetine hydrochloride hemihydrate from Mylan Pharmaceuticals, confirming the continued author…
-
FDA approval · 2013-12-19FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Venlafaxine Hydrochloride by Aurobindo Pharma Limited, updating the regulatory status of thi…
-
FDA approval · 2013-12-19FDA Approved: PAROXETINE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for paroxetine submitted by Padagis US LLC (NDA 204516).
-
FDA approval · 2013-12-19FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for escitalopram oxalate from Amneal Pharmaceuticals LLC under ANDA202227, enabling continued co…
-
CLINICAL_TRIALS trial_result · 2013-12-18Clinical Trial Update: Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder [Phase 3]
Phase 3 trial evaluating the efficacy of vortioxetine for generalized anxiety disorder; results were posted in December 2013.
-
CLINICAL_TRIALS trial_result · 2013-12-18Clinical Trial Update: An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder [Phase 3]
This update reports results from a Phase 3 efficacy and safety study of vortioxetine for generalized anxiety disorder. The trial has complet…
-
CLINICAL_TRIALS trial_result · 2013-12-18Clinical Trial Update: Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder [Phase 3]
A Phase 3 trial evaluating vortioxetine (Lu AA21004) for generalized anxiety disorder has completed, with results posted in 2013. The update…
-
FDA approval · 2013-12-17FDA Approved: DULOXETINE — Original Application (Actavis Pharma, Inc.)
FDA approved Actavis Pharma, Inc.'s original application for a generic duloxetine product. The approval makes low-cost generic duloxetine av…
-
FDA approval · 2013-12-11FDA Approved: DULOXETINE — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for a generic duloxetine hydrochloride product from Aurobindo Pharma Limited.
-
FDA approval · 2013-12-11FDA Approved: DULOXETINE — Original Application (MARKSANS PHARMA LIMITED)
FDA approves duloxetine hydrochloride generic by Marksans Pharma Limited under an Original ANDA (ANDA 090723).
-
FDA approval · 2013-12-11FDA Approved: DULOXETINE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical Industries' original application for a generic duloxetine product (DULOXETINE). This approval allows the mar…
-
FDA approval · 2013-12-11FDA Approved: DULOXETINE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' generic duloxetine under an Original Application, authorizing a generic version of the reference duloxet…
-
CLINICAL_TRIALS trial_result · 2013-12-06Clinical Trial Update: Lorazepam-Induced Toxicity in the Aged [Phase 4]
Phase 4 clinical trial update highlighting lorazepam-associated toxicity in older adults, raising safety considerations for patients with an…
-
CLINICAL_TRIALS trial_result · 2013-11-21Clinical Trial Update: Prevalence and Effect of Detecting Common Mental Disorders in Long-term Sickness Absence [NA]
A completed clinical trial update examining the prevalence of common mental disorders in individuals with long-term sickness absence and the…
-
CLINICAL_TRIALS research · 2013-11-20Clinical Trial Update: Evaluating the Effects of Stress in Pregnancy
A completed clinical trial investigates how stress during pregnancy may affect major depressive disorder, panic disorder, generalized anxiet…
-
CLINICAL_TRIALS trial_result · 2013-11-11Clinical Trial Update: Muscle Relaxation Therapy With Odorant Cue [NA]
A completed clinical trial from Emory University evaluated muscle relaxation therapy using an odorant cue for generalized anxiety disorder a…
-
CLINICAL_TRIALS research · 2013-11-06Clinical Trial Update: Acceptance-Based Treatment for Generalized Anxiety Disorder [Phase 1]
A Phase 1 clinical trial update reports completion of a study testing acceptance-based treatment for Generalized Anxiety Disorder.
-
CLINICAL_TRIALS trial_result · 2013-10-11Clinical Trial Update: Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD) [Phase 3]
Phase 3 trial evaluating quetiapine extended-release (XR) for bipolar disorder patients with comorbid generalized anxiety disorder; results …
-
FDA approval · 2013-09-19FDA Approved: ALPRAZOLAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved the supplemental application for Alprazolam from Aurobindo Pharma Limited (generic alprazolam). The approval pertains to a supp…